



=> d l1; d l4; d his; log y  
L1 HAS NO ANSWERS  
L1 STR



Structure attributes must be viewed using STN Express query preparation.  
L4 HAS NO ANSWERS  
L4 STR



Structure attributes must be viewed using STN Express query preparation.

(FILE 'HOME' ENTERED AT 19:50:42 ON 15 MAY 2003)

FILE 'REGISTRY' ENTERED AT 19:50:48 ON 15 MAY 2003

L1 STRUCTURE UPLOADED  
L2 9 S L1  
L3 1179 S L1 FUL  
L4 STRUCTURE UPLOADED  
L5 6 S L4 SAM SUB=L3  
L6 201 S L4 FUL SUB=L3  
L7 978 S L3 NOT L6

FILE 'CAPLUS' ENTERED AT 19:52:12 ON 15 MAY 2003

L8 85 S L7

|  |            |         |
|--|------------|---------|
| COST IN U.S. DOLLARS                       | SINCE FILE | TOTAL   |
|  | ENTRY      | SESSION |
| FULL ESTIMATED COST                        | 388.48     | 572.14  |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE | TOTAL   |
|  | ENTRY      | SESSION |
| CA SUBSCRIBER PRICE                        | -55.34     | -55.34  |

STN INTERNATIONAL LOGOFF AT 19:56:18 ON 15 MAY 2003

L8 ANSWER 21 OF 85 CAPIUS COPYRIGHT 2003 ACS

AN 2000:227868 CAPLUS

DN 132:262407

TI Biological reagents and methods for determining the mechanism in the generation of .beta.-amyloid peptide

IN Audia, James E.; Hyslop, Paul A.; Nissen, Jeffrey S.; Thompson, Richard C.; Tung, Jay S.; Tanner, Laura I.

PA Elan Pharmaceuticals, Inc., USA; Eli Lilly and Company

SO PCT Int. Appl., 86 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

|    | PATENT NO.    | KIND | DATE     | APPLICATION NO. | DATE     |
|----|---------------|------|----------|-----------------|----------|
| PI | WO 2000019210 | A2   | 20000406 | WO 1999-US22684 | 19990929 |
|    | WO 2000019210 | A3   | 20010118 |                 |          |

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9962780 A1 20000417 AU 1999-62780 19990929

EP 1131634 A2 20010912 EP 1999-950039 19990929

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

US 6486350 B1 20021126 US 1999-408283 19990929

US 2003069445 A1 20030410 US 2002-217459 20020814

PRAI US 1998-160082P P 19980930

US 1999-408283 A3 19990929

WO 1999-US22684 W 19990929

OS MARPAT 132:262407

AB Biol. reagents are described which comprise compds. that inhibit .beta.-amyloid peptide release and/or its synthesis. These compds. have utility in detg. the cellular mechanism involved in the generation of .beta.-amyloid peptide. The synthesis of these compds. are described extensively.

IT 209984-57-6P


RL: ARU (Analytical role, unclassified); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); SPN (Synthetic preparation); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(synthesis of biol. reagents and methods for detg. mechanism in generation of .beta.-amyloid peptide)

RN 209984-57-6 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro-.alpha.-hydroxy-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 209984-58-7P 209984-68-9P

RL: ARU (Analytical role, unclassified); BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified);

SPN

(Synthetic preparation); ANST (Analytical study); BIOL (Biological study);


PREP (Preparation); PROC (Process); USES (Uses)

(synthesis of biol. reagents and methods for detg. mechanism in generation of .beta.-amyloid peptide)

RN 209984-58-7 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro-α-hydroxy-, (α.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 209984-68-9 CAPLUS

CN Butanamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-2-hydroxy-3-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 209984-35-0 253324-50-4


RL: RCT (Reactant); RACT (Reactant or reagent)

(synthesis of biol. reagents and methods for detg. mechanism in generation of .beta.-amyloid peptide)

RN 209984-35-0 CAPLUS

CN Propanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 253324-50-4 CAPLUS

CN Propanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 26 OF 85 CAPLUS COPYRIGHT 2003 ACS  
 AN 1999:819352 CAPLUS  
 DN 132:64533  
 TI Preparation of cyclic amino acid compounds for inhibiting .beta.-amyloid peptide release and/or its synthesis  
 IN Audia, James E.; Thompson, Richard C.; Wilkie, Stephen C.; Britton, Thomas C.; Porter, Warren J.; Huffman, George W.; Latimer, Lee H.  
 PA Elan Pharmaceuticals, Inc., USA; Eli Lilly & Company  
 SO PCT Int. Appl., 271 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

|       | PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE     |
|-------|---|------|----------|-----------------|----------|
| PI    | WO 9967220  | A1   | 19991229 | WO 1999-US14007 | 19990621 |
|       | W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM |      |          |                 |          |
|       | RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  |      |          |                 |          |
|       | CA 2325388  | AA   | 19991229 | CA 1999-2325388 | 19990621 |
|       | AU 9952047  | A1   | 20000110 | AU 1999-52047   | 19990621 |
|       | EP 1089981  | A1   | 20010411 | EP 1999-937164  | 19990621 |
|       | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI   |      |          |                 |          |
|       | JP 2002518482   | T2   | 20020625 | JP 2000-555874  | 19990621 |
|       | US 6509331  | B1   | 20030121 | US 1999-337484  | 19990621 |
| PRAI  | US 1998-102728  | A2   | 19980622 |                 |          |
|       | US 1998-155265P   | P    | 19980622 |                 |          |
|       | WO 1999-US14007   | W    | 19990621 |                 |          |
| OS    | MARPAT 132:64533  |      |          |                 |          |
| AB    | Compds. R1(Z)mNH(Y)nW [W is a fused ring system, e.g., benzo- or dibenzoazepinones or -diazepinones; Y = CHR2CONH or (CHR2')aNH, where R2 =   |      |          |                 |          |
|       | (un)substituted alkyl, alkenyl, or alkynyl, cycloalkyl, aryl, heteroaryl,   |      |          |                 |          |
|       | heterocyclyl, R2' = H or R2; R1 = (un)substituted alkyl, alkenyl, alkynyl,  |      |          |                 |          |
|       | cycloalkyl, or cycloalkenyl, aryl, heteroaryl, heterocyclyl, Z = -T-CX'X''CO, where T is selected from the group consisting of a bond covalently linking R1 to -CX'X''-, oxygen, sulfur and -NR6 (R6 = H, acyl,   |      |          |                 |          |
|       | alkyl, aryl, heteroaryl), X' is H, OH, F, X'' is H, OH, F or X' and X'' together form an oxo group; m = 0 or 1; n = 1 or 2] were prepd. for inhibition of .beta.-amyloid peptide release and/or its synthesis.  |      |          |                 |          |
| Thus, | 1-(L-alaninylamino)-4,5,6,7-tetrahydro-3,7-methano-3H-3-benzazonin-2(1H)-one was prepd. via coupling of N-tert-butoxycarbonyl-L-alanine with 1-amino-4,5,6,7-tetrahydro-3,7-methano-3H-3-benzazonin-2(1H)-one.  |      |          |                 |          |
|       | Compds.   |      |          |                 |          |

of the invention inhibit .beta.-amyloid peptide prodn. by at least 30% as compared to the control when employed at 10 .mu.g/mL.


IT 209994-99-0P 228877-30-3P 228877-32-5P  
228877-95-0P 229021-48-1P 253185-47-6P  
253185-49-8P 253185-51-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of cyclic amino acid compds. for inhibiting .beta.-amyloid peptide release)

RN 209994-99-0 CAPLUS

CN Propanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-30-3 CAPLUS

CN Butanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-32-5 CAPLUS

CN Butanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3,3-dimethyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-95-0 CAPLUS

CN Propanamide, 2-amino-N-(5,6,8,9-tetrahydro-8-oxo-4H-benzo[d]pyrido[3,2,1-jk][1]benzazepin-9-yl)-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 229021-48-1 CAPLUS

CN Propanamide, 2-amino-N-(1,2,4,5,6,7-hexahydro-2-oxo-3,7-methano-3H-3-benzazonin-1-yl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253185-47-6 CAPLUS

CN Propanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, (2S)- (9CI) (CA INDEX NAME)

yl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253185-49-8 CAPLUS

CN Butanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-

yl)-3-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253185-51-2 CAPLUS

CN Butanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-

yl)-3,3-dimethyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 228877-28-9P 228877-29-0P 228877-31-4P



228877-58-5P 229021-47-0P 253185-46-5P  
253185-48-7P 253185-50-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT

(Reactant or reagent)

(prep. of cyclic amino acid compds. for inhibiting .beta.-amyloid  
peptide release)

RN 228877-28-9 CAPLUS


CN Carbamic acid, [(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-  
dibenz[b,d]azepin-7-

yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA

INDEX

NAME)

Absolute stereochemistry.



RN 228877-29-0 CAPLUS


CN Carbamic acid, [(1S)-1-[[ (6,7-dihydro-5-methyl-6-oxo-5H-  
dibenz[b,d]azepin-

7-yl)amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI)

(CA

INDEX NAME)

Absolute stereochemistry.




RN 228877-31-4 CAPLUS

CN Carbamic acid, [(1S)-1-[[ (6,7-dihydro-5-methyl-6-oxo-5H-

dibenz[b,d]azepin-

7-yl)amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 228877-58-5 CAPLUS

CN Carbamic acid, [(1S)-1-methyl-2-oxo-2-[(5,6,8,9-tetrahydro-8-oxo-4H-benzo[d]pyrido[3,2,1-jk][1]benzazepin-9-yl)amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229021-47-0 CAPLUS


CN Carbamic acid, [(1S)-2-[(1,2,4,5,6,7-hexahydro-2-oxo-3,7-methano-3H-3-benzazonin-1-yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253185-46-5 CAPLUS  
 CN Carbamic acid, [(1R)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA  
 INDEX  
 NAME)

Absolute stereochemistry.



RN 253185-48-7 CAPLUS  
 CN Carbamic acid, [(1R)-1-[[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI)  
 (CA  
 INDEX NAME)


Absolute stereochemistry.



RN 253185-50-1 CAPLUS

CN Carbamic acid, [(1R)-1-[[[6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4      THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 27 OF 85 CAPLUS COPYRIGHT 2003 ACS

AN 1999:819351 CAPLUS

DN 132:64532

TI Preparation of cyclic amino acid compounds for inhibiting .beta.-amyloid peptide release and/or its synthesis

IN Audia, James E.; Porter, Warren J.; Thompson, Richard C.; Wilkie, Stephen

C.; Stack, Douglas R.; Shi, Qing

PA Elan Pharmaceuticals, Inc., USA; Eli Lilly & Company

SO PCT Int. Appl., 287 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

|      | PATENT NO.      | KIND   | DATE     | APPLICATION NO. | DATE     |
|------|-----------------|--|----------|-----------------|----------|
| PI   | WO 9967219      | A1   | 19991229 | WO 1999-US14096 | 19990622 |
|      | W:              | AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM |          |                 |          |
|      | RW:             | GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG   |          |                 |          |
|      | CA 2324474      | AA   | 19991229 | CA 1999-2324474 | 19990622 |
|      | AU 9947079      | A1   | 20000110 | AU 1999-47079   | 19990622 |
|      | EP 1089977      | A1   | 20010411 | EP 1999-930566  | 19990622 |
|      | R:              | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI   |          |                 |          |
|      | JP 2002518481   | T2   | 20020625 | JP 2000-555873  | 19990622 |
|      | US 6552013      | B1   | 20030422 | US 1999-338121  | 19990622 |
| PRAI | US 1998-102507  | A2   | 19980622 |                 |          |
|      | US 1998-162757  | A2   | 19980930 |                 |          |
|      | US 1998-160067P | P  | 19980622 |                 |          |
|      | US 1998-150704P | P  | 19980930 |                 |          |
|      | WO 1999-US14096 | W  | 19990622 |                 |          |

OS MARPAT 132:64532

AB Comps. R1ZNH(Y)nW [W is a fused ring system, e.g., benzo- or dibenzoazepinones or -diazepinones; Y = CHR2CONH, where R2 = (un)substituted alkyl, alkenyl, or alkynyl, cycloalkyl, aryl,

heteroaryl,

heterocyclyl; R1 = (un)substituted alkyl, alkenyl, cycloalkyl, or cycloalkenyl, aryl, heteroaryl, heterocyclyl; Z is represented by -T-CX'X''V- where T is selected from the group consisting of a bond covalently linking R1 to -CX'X''-, oxygen, sulfur and -NR6 (R6 = H,

acyl,

alkyl, aryl, heteroaryl), X' is H, OH, F, X'' is H, OH, F or X' and X'' together form an oxo group, V is alkylene or substituted alkylene or R1 and Z together form aryl or (un)substituted cycloalkyl, cycloalkenyl, or heterocyclyl; n = 1 or 2] were prepd. for inhibition of .beta.-amyloid peptide release and/or its synthesis. Thus, 5-(S)-[N'-(2-(3,5-difluorophenyl)ethyl)-L-alaninyl]amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one was prepd. by reductive alkylation of 5-(S)-(L-alaninyl)amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one hydrochloride with 3,5-difluorophenylacetaldehyde using sodium

cyanoborohydride. Compds. of the invention inhibit .beta.-amyloid peptide prodn. by at least 30% as compared to the control when employed at 10 .mu.g/mL.


IT 253161-81-8P 253161-91-0P 253161-92-1P  
253161-93-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(prepn. of cyclic amino acid compds. for inhibiting .beta.-amyloid peptide release)

RN 253161-81-8 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-  
2-[[[(1R,2S)-1,2,3,4-tetrahydro-1-hydroxy-2-naphthalenyl]amino]-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253161-91-0 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-  
2-[[[(1S,2S)-1,2,3,4-tetrahydro-1-hydroxy-2-naphthalenyl]amino]-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253161-92-1 CAPLUS


CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-  
2-[[[(1S,2R)-1,2,3,4-tetrahydro-1-hydroxy-2-naphthalenyl]amino]-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253161-93-2 CAPLUS  
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-  
 2-[[[(1R,2R)-1,2,3,4-tetrahydro-1-hydroxy-2-naphthalenyl]amino]-, (2S)-  
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 209984-35-0P 209984-36-1P 209984-39-4P  
 209984-40-7P 229021-48-1P 253135-42-1P  
 253136-05-9P 253161-60-3P 253161-61-4P  
 253161-62-5P 253161-63-6P 253161-64-7P  
 253161-65-8P 253161-66-9P 253161-67-0P  
 253161-68-1P 253161-69-2P 253161-70-5P  
 253161-71-6P 253161-72-7P 253161-73-8P  
 253161-74-9P 253161-76-1P 253161-77-2P  
 253161-78-3P 253161-82-9P 253161-83-0P  
 253161-84-1P 253161-85-2P 253161-86-3P  
 253161-95-4P

RL: BAC (Biological activity or effector, except adverse); BSU  
 (Biological  
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic  
 use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of cyclic amino acid compds. for inhibiting .beta.-amyloid  
 peptide release)  
 RN 209984-35-0 CAPLUS  
 CN Propanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-  
 dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX  
 NAME)


Absolute stereochemistry.



● HCl

RN 209984-36-1 CAPLUS  
 CN Propanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 209984-39-4 CAPLUS  
 CN Butanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HCl

RN 209984-40-7 CAPLUS

CN Butanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 229021-48-1 CAPLUS

CN Propanamide, 2-amino-N-(1,2,4,5,6,7-hexahydro-2-oxo-3,7-methano-3H-benzazonin-1-yl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253135-42-1 CAPLUS

CN Propanamide, 2-amino-N-[6,7-dihydro-5-(2-methylpropyl)-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

NAME)

Absolute stereochemistry.




● HCl

RN 253136-05-9 CAPLUS

CN Propanamide, 2-amino-N-(2,3,4,5-tetrahydro-1-methyl-2-oxo-5-phenyl-1H-1-benzazepin-3-yl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253161-60-3 CAPLUS

CN Propanamide, 2-[[2-(3,5-difluorophenyl)ethyl]amino]-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-61-4 CAPLUS

CN Propanamide, 2-[[[(2R)-2-(3,5-difluorophenyl)-2-hydroxyethyl]amino]-N-[(7S)-


6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-62-5 CAPLUS  
 CN Propanamide, 2-[[ (2S)-2-(3,5-difluorophenyl)-2-hydroxyethyl]amino]-N-  
 [(7S)-  
 6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-63-6 CAPLUS  
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-  
 2-[[2-hydroxy-3-(1-methylethoxy)propyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-64-7 CAPLUS  
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-  
 2-[(2-hydroxybutyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-65-8 CAPLUS  
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-  
 2-[(2,3-dihydroxypropyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253161-66-9 CAPLUS  
 CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-  
 2-[[2-hydroxy-3-(4-morpholinyl)propyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-67-0 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-

2-[(2S)-2-hydroxy-4-(morpholin-4-yl)butyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-68-1 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-

2-[(2S)-2-hydroxyoctyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-69-2 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-


2-[[2R]-2-hydroxy-2-(3,4,5-trifluorophenyl)ethyl]amino]-, (2S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 253161-70-5 CAPLUS  
CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-  
2-[[2-((2S)-2-hydroxy-2-(3,4,5-trifluorophenyl)ethyl)amino]-, (2S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



RN 253161-71-6 CAPLUS  
CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-  
2-[[2-((2R)-2-hydroxy-2-[4-(trifluoromethyl)phenyl]ethyl)amino]-, (2S)-  
(9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 253161-72-7 CAPLUS  
CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-  
2-[[2-((2S)-2-hydroxy-2-[4-(trifluoromethyl)phenyl]ethyl)amino]-, (2S)-

(9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 253161-73-8 CAPLUS

CN Propanamide, 2-[[ (2R)-2-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxyethyl]amino]-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253161-74-9 CAPLUS

CN Propanamide, 2-[[ (2S)-2-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxyethyl]amino]-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-76-1 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-[[ (2S)-3,3,3-trifluoro-2-hydroxypropyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

NAME)

Absolute stereochemistry.




RN 253161-77-2 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-

2-[(3-methyl-2-oxobutyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-78-3 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-

2-[[ (2S)-2-hydroxy-3-methylbutyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






yl]-

2-[(1,2,3,4-tetrahydro-2-naphthalenyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-85-2 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-

2-[(2-hydroxycyclohexyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253161-86-3 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-

2-[(4-methylpentyl)amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253161-95-4 CAPLUS

CN L-Alaninamide, N-(4-methylpentyl)-L-valyl-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 209984-33-8P 209984-34-9P 209984-37-2P  
 209984-38-3P 209984-41-8P 209984-42-9P  
 209984-43-0P 209984-44-1P 228877-58-5P  
 228877-95-0P 229021-47-0P 253135-43-2P  
 253136-04-8P 253161-58-9P 253161-75-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT


(Reactant or reagent)

(prepn. of cyclic amino acid compds. for inhibiting .beta.-amyloid peptide release)

RN 209984-33-8 CAPLUS

CN Carbamic acid, [(1S)-2-[[ (7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-34-9 CAPLUS


CN Carbamic acid, [(1S)-2-[[ (7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209984-37-2 CAPLUS  
 CN Carbamic acid, [(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl  
 ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209984-38-3 CAPLUS  
 CN Carbamic acid, [(1S)-1-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl  
 ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-41-8 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-42-9 CAPLUS


CN Carbamic acid, [(1S)-1-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209984-43-0 CAPLUS  
 CN Butanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3,3-dimethyl-, monohydrochloride, (2S)- (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-44-1 CAPLUS  
 CN Butanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3,3-dimethyl-, monohydrochloride, (2S)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 228877-58-5 CAPLUS

CN Carbamic acid, [(1S)-1-methyl-2-oxo-2-[(5,6,8,9-tetrahydro-8-oxo-4H-benzo[d]pyrido[3,2,1-jk][1]benzazepin-9-yl)amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-95-0 CAPLUS

CN Propanamide, 2-amino-N-(5,6,8,9-tetrahydro-8-oxo-4H-benzo[d]pyrido[3,2,1-jk][1]benzazepin-9-yl)-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 229021-47-0 CAPLUS

CN Carbamic acid, [(1S)-2-[(1,2,4,5,6,7-hexahydro-2-oxo-3,7-methano-3H-3-benzazonin-1-yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253135-43-2 CAPLUS

CN Carbamic acid, [(1S)-2-[(6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253136-04-8 CAPLUS


CN Carbamic acid, [(1S)-1-methyl-2-oxo-2-[(2,3,4,5-tetrahydro-1-methyl-2-oxo-5-phenyl-1H-1-benzazepin-3-yl)amino]ethyl]-, 1,1-dimethylethyl ester



(9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 253161-58-9 CAPLUS

CN 5,7-Dioxa-10-aza-2-siladodecan-12-amide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2,2,11-trimethyl-8-(1-methylethyl)-, (8S,11S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253161-75-0 CAPLUS

CN Propanamide, N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-[[[(2R)-3,3,3-trifluoro-2-hydroxypropyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 28 OF 85 CAPLUS COPYRIGHT 2003 ACS  
 AN 1999:819249 CAPLUS  
 DN 132:64531  
 TI Preparation of cyclic amino acid compounds for inhibiting .beta.-amyloid peptide release and/or its synthesis  
 IN Audia, James E.; Dressman, Bruce A.; Shi, Qing  
 PA Elan Pharmaceuticals, Inc., USA; Eli Lilly & Company  
 SO PCT Int. Appl., 256 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 4

|       | PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE     |
|-------|---|------|----------|-----------------|----------|
| PI    | WO 9966934  | A1   | 19991229 | WO 1999-US14211 | 19990622 |
|       | W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM<br>RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG |      |          |                 |          |
|       | CA 2324475  | AA   | 19991229 | CA 1999-2324475 | 19990622 |
|       | AU 9947104  | A1   | 20000110 | AU 1999-47104   | 19990622 |
|       | EP 1093372  | A1   | 20010425 | EP 1999-930600  | 19990622 |
|       | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI   |      |          |                 |          |
|       | JP 2002518451   | T2   | 20020625 | JP 2000-555620  | 19990622 |
| PRAI  | US 1998-102507  | A2   | 19980622 |                 |          |
|       | US 1998-164451  | A2   | 19980930 |                 |          |
|       | WO 1999-US14211   | W    | 19990622 |                 |          |
| OS    | MARPAT 132:64531  |      |          |                 |          |
| AB    | Compds. R'R''NCHR1CONH(Y)nW and R':NC(:R1)CONH(Y)nW [W is a fused ring system, e.g., benzo- or dibenzazepinones or -diazepinones; Y = CHR2CONH, where R2 = (un)substituted alkyl, alkenyl, or alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl; R1 and R' form a nitrogen-contg. heterocycle; R'' = H, alkyl, substituted alkyl, aryl; n = 1 or 2] were prep'd. for inhibition of .beta.-amyloid peptide release and/or its synthesis.   |      |          |                 |          |
| Thus, | 5-(S)-[N'-(L-prolyl)-L-alaninyl]amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one was prep'd. via coupling of N-(N'-tert-butoxycarbonyl-L-prolyl)-L-alanine with 5-(S)-amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one. Compds. of the invention inhibit .beta.-amyloid peptide prodn. by at least 30% as compared to the control when employed at 10 .mu.g/mL.   |      |          |                 |          |
| IT    | 209984-35-0P 209984-36-1P 209984-39-4P<br>209984-40-7P 209984-43-0P 209984-44-1P<br>229021-48-1P 253135-42-1P 253136-05-9P<br>253136-07-1P 253136-11-7P 253136-15-1P<br>253136-19-5P 253136-20-8P 253136-23-1P<br>253136-27-5P 253136-32-2P 253136-36-6P<br>253136-39-9P 253136-41-3P 253136-43-5P<br>253136-45-7P 253136-52-6P 253136-53-7P  |      |          |                 |          |

253136-61-7P 253136-65-1P 253136-66-2P  
 253136-68-4P 253136-69-5P 253136-71-9P  
 253136-74-2P 253136-75-3P 253136-76-4P  
 253136-77-5P 253194-30-8P 253194-32-0P  
 253194-34-2P

RL: BAC (Biological activity or effector, except adverse); BSU  
 (Biological  
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic  
 use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of cyclic amino acid compds. for inhibiting .beta.-amyloid  
 peptide release)  
 RN 209984-35-0 CAPLUS  
 CN Propanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-  
 dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX  
 NAME)


Absolute stereochemistry.



● HCl

RN 209984-36-1 CAPLUS  
 CN Propanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-  
 dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX  
 NAME)


Absolute stereochemistry.



HCl

RN 209984-39-4 CAPLUS  
 CN Butanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-40-7 CAPLUS  
 CN Butanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-43-0 CAPLUS  
 CN Butanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3,3-dimethyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-44-1 CAPLUS  
 CN Butanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3,3-dimethyl-, monohydrochloride, (2S)- (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 229021-48-1 CAPLUS  
 CN Propanamide, 2-amino-N-(1,2,4,5,6,7-hexahydro-2-oxo-3,7-methano-3H-3-benzazonin-1-yl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253135-42-1 CAPLUS  
 CN Propanamide, 2-amino-N-[6,7-dihydro-5-(2-methylpropyl)-6-oxo-5H-

dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 253136-05-9 CAPLUS

CN Propanamide, 2-amino-N-(2,3,4,5-tetrahydro-1-methyl-2-oxo-5-phenyl-1H-1-benzazepin-3-yl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-07-1 CAPLUS

CN L-Alaninamide, L-prolyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-11-7 CAPLUS

CN 2-Piperidinecarboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-15-1 CAPLUS

CN 2-Piperidinecarboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-19-5 CAPLUS

CN 1-Isoquinolinecarboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-1,2,3,4-tetrahydro-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-20-8 CAPLUS


CN 1-Isoquinolinecarboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-1,2,3,4-tetrahydro-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-23-1 CAPLUS  
 CN L-Alaninamide, (4S)-4-(3-methylbutyl)-L-prolyl-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253136-27-5 CAPLUS  
 CN L-Alaninamide, (4R)-4-(3-methylbutyl)-L-prolyl-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-32-2 CAPLUS  
 CN 1H-Indole-2-carboxamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-2,3-dihydro-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 253136-36-6 CAPLUS

CN 1H-Indole-2-carboxamide, N-[(1S)-2-[[ (7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-2,3-dihydro-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-39-9 CAPLUS

CN L-Alaninamide, (4R)-4-hydroxy-L-prolyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-41-3 CAPLUS

CN L-Alaninamide, (4R)-4-hydroxy-L-prolyl-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-43-5 CAPLUS

CN 2-Quinolinecarboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-1,2,3,4-tetrahydro-, (2R)-(9CI)] (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-45-7 CAPLUS

CN 2-Quinolinecarboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-1,2,3,4-tetrahydro-, (2S)-(9CI)] (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-52-6 CAPLUS

CN 1H-Indole-2-carboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-2,3-dihydro-3,3-dimethyl-, (2R)-(9CI)] (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-53-7 CAPLUS

CN 1H-Indole-2-carboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-2,3-dihydro-3,3-dimethyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-61-7 CAPLUS

CN 1H-Indole-2-carboxamide, N-[(1S)-2-[[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino)-1-methyl-2-oxoethyl]-2,3-dihydro-2-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-65-1 CAPLUS

CN 1H-Indole-2-carboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino)-1-methyl-2-oxoethyl]-2,3-dihydro-2-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-66-2 CAPLUS


CN 1H-Indole-2-carboxamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-68-4 CAPLUS

CN 1H-Indole-2-carboxamide, 2,3-dihydro-3,3-dimethyl-N-[(1S)-1-methyl-2-oxo-2-[[[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]amino]ethyl]-, (2R)- (9CI) (CA INDEX NAME)



RN 253136-69-5 CAPLUS

CN 1H-Indole-2-carboxamide, 2,3-dihydro-3,3-dimethyl-N-[(1S)-1-methyl-2-oxo-2-[[[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]amino]ethyl]-, (2S)- (9CI) (CA INDEX NAME)




RN 253136-71-9 CAPLUS

CN 2-Quinolonecarboxamide, 1,2,3,4-tetrahydro-N-[(1S)-1-methyl-2-oxo-2-[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]amino]ethyl]- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 253136-74-2 CAPLUS

CN 2-Quinolonecarboxamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-75-3 CAPLUS

CN 2-Piperidinecarboxamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-76-4 CAPLUS

CN 2-Quinolonecarboxamide, 1,2,3,4-tetrahydro-N-[(1S)-1-methyl-2-oxo-2-[[[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]amino]ethyl]-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 253136-77-5 CAPLUS

CN 2-Quinolonecarboxamide, 1,2,3,4-tetrahydro-N-[(1S)-1-methyl-2-oxo-2-[[[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]amino]ethyl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 253194-30-8 CAPLUS

CN 1H-Indole-2-carboxamide, N-[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]octahydro-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253194-32-0 CAPLUS

CN 2-Quinolinecarboxamide, N-[(1S)-2-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]decahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253194-34-2 CAPLUS

CN 2-Quinolinecarboxamide, N-[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]decahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 253136-51-5 253136-72-0


RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of cyclic amino acid compds. for inhibiting .beta.-amyloid peptide release)

RN 253136-51-5 CAPLUS

CN 1H-Indole-1-carboxylic acid, 2-[[[(1S)-2-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-2,3-dihydro-3,3-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-72-0 CAPLUS

CN Propanamide, 2-amino-N-[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 209984-33-8P 209984-34-9P 209984-37-2P  
209984-38-3P 209984-41-8P 209984-42-9P  
228877-58-5P 228877-95-0P 229021-47-0P  
253135-43-2P 253136-04-8P 253136-06-0P  
253136-10-6P 253136-14-0P 253136-18-4P  
253136-21-9P 253136-26-4P 253136-31-1P  
253136-34-4P 253136-38-8P 253136-42-4P  
253136-59-3P 253136-63-9P 253136-67-3P  
253136-70-8P 253194-29-5P 253194-31-9P  
253194-33-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT

(Reactant or reagent)


(prepn. of cyclic amino acid compds. for inhibiting .beta.-amyloid peptide release)

RN 209984-33-8 CAPLUS

CN Carbamic acid, [(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 209984-34-9 CAPLUS

CN Carbamic acid, [(1S)-2-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-37-2 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-38-3 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-41-8 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-42-9 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-58-5 CAPLUS


CN Carbamic acid, [(1S)-1-methyl-2-oxo-2-[(5,6,8,9-tetrahydro-8-oxo-4H-benzo[d]pyrido[3,2,1-jk][1]benzazepin-9-yl)amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228877-95-0 CAPLUS  
 CN Propanamide, 2-amino-N-(5,6,8,9-tetrahydro-8-oxo-4H-benzo[d]pyrido[3,2,1-jk][1]benzazepin-9-yl)-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 229021-47-0 CAPLUS  
 CN Carbamic acid, [(1S)-2-[(1,2,4,5,6,7-hexahydro-2-oxo-3,7-methano-3H-3-benzazonin-1-yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253135-43-2 CAPLUS  
 CN Carbamic acid, [(1S)-2-[(6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-


yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA  
INDEX  
NAME)

Absolute stereochemistry.




RN 253136-04-8 CAPLUS  
CN Carbamic acid, [(1S)-1-methyl-2-oxo-2-[(2,3,4,5-tetrahydro-1-methyl-2-oxo-5-phenyl-1H-1-benzazepin-3-yl)amino]ethyl]-, 1,1-dimethylethyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



RN 253136-06-0 CAPLUS  
CN L-Alaninamide, 1-[(1,1-dimethylethoxy)carbonyl]-L-prolyl-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-10-6 CAPLUS  
CN 1-Piperidinecarboxylic acid, 2-[[[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-

oxo-

5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-,  
1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-14-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 2-[[[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-

5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-18-4 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 1-[[[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-

6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-

3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-21-9 CAPLUS

CN L-Alaninamide, (4S)-1-[(1,1-dimethylethoxy)carbonyl]-4-(3-methylbutyl)-

L-prolyl-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 253136-26-4 CAPLUS

CN L-Alaninamide, (4R)-1-[(1,1-dimethylethoxy)carbonyl]-4-(3-methylbutyl)-  
L-  
prolyl-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 253136-31-1 CAPLUS

CN 1H-Indole-1-carboxylic acid, 2-[[[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-  
5H-  
dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]amino]carbonyl]-2,3-  
dihydro-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-34-4 CAPLUS

CN 1H-Indole-1-carboxylic acid, 2-[[[(1S)-2-[(7S)-6,7-dihydro-5-methyl-6-  
oxo-  
5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-  
2,3-

dihydro-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-38-8 CAPLUS

CN L-Alaninamide, (4R)-1-[(1,1-dimethylethoxy)carbonyl]-4-hydroxy-L-prolyl-N-  
N-  
(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253136-42-4 CAPLUS

CN 1(2H)-Quinolinecarboxylic acid, 2-[[[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-59-3 CAPLUS

CN 1H-Indole-1-carboxylic acid, 2-[[[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-  
5H-  
dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]amino]carbonyl]-2,3-



dihydro-2-methyl-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-63-9 CAPLUS

CN 1H-Indole-1-carboxylic acid, 2-[[[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-

5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-2,3-

dihydro-2-methyl-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253136-67-3 CAPLUS

CN 1H-Indole-1-carboxylic acid, 2,3-dihydro-3,3-dimethyl-2-[[[(1S)-1-methyl-2-

oxo-2-[[[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]amino]ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA

INDEX

NAME)




RN 253136-70-8 CAPLUS

CN 1(2H)-Quinolinecarboxylic acid, 3,4-dihydro-2-[[[(1S)-1-methyl-2-oxo-2-[[[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-


yl]amino]ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA  
INDEX  
NAME)

Absolute stereochemistry.




RN 253194-29-5 CAPLUS  
CN 1H-Indole-1-carboxylic acid, 2-[[[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-6-  
oxo-  
5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-  
oxoethyl]amino]carbonyl]octahy  
dro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253194-31-9 CAPLUS  
CN 1(2H)-Quinolonecarboxylic acid, 2-[[[(1S)-2-[[[(7S)-6,7-dihydro-5-methyl-  
6-  
oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-  
oxoethyl]amino]carbonyl]octahydro-, 1,1-dimethylethyl ester (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.




RN 253194-33-1 CAPLUS

CN 1(2H)-Quinolinecarboxylic acid, 2-[[[(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-

5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]amino]carbonyl]octahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 35 OF 85 CAPLUS COPYRIGHT 2003 ACS  
 AN 1999:425778 CAPLUS  
 DN 131:73572  
 TI Preparation of annelated caprolactams as inhibitors of .beta.-amyloid  
 release and/or synthesis.  
 IN Audia, James E.; Mabry, Thomas E.; Nissen, Jeffrey S.; Mcdaniel, Stacey  
 L.  
 PA Elan Pharmaceuticals, Inc., USA; Eli Lilly and Company  
 SO PCT Int. Appl., 114 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

|    | PATENT NO.   | KIND | DATE     | APPLICATION NO. | DATE     |
|----|--|------|----------|-----------------|----------|
| PI | WO 9932453   | A1   | 19990701 | WO 1998-US22637 | 19981029 |
|    | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,<br>DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP,<br>KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,<br>MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,<br>TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU,<br>TJ, TM<br>RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,<br>FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,<br>CM, GA, GN, GW, ML, MR, NE, SN, TD, TG<br>CA 2307221 AA 19990701 CA 1998-2307221 19981029<br>AU 9912777 A1 19990712 AU 1999-12777 19981029<br>BR 9812773 A 20001010 BR 1998-12773 19981029<br>EP 1042298 A1 20001011 EP 1998-956198 19981029<br>R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,<br>IE, SI, LT, LV, FI, RO<br>US 2002068741 A1 20020606 US 2001-915263 20010726<br>US 2002052359 A1 20020502 US 2001-915480 20010727<br>US 6544978 B2 20030408<br>US 2002111343 A1 20020815 US 2001-915547 20010727<br>US 2002115652 A1 20020822 US 2001-915362 20010727<br>US 6541466 B2 20030401<br>US 2002123486 A1 20020905 US 2001-915342 20010727<br>US 2002137738 A1 20020926 US 2001-915564 20010727<br>US 6559141 B2 20030506<br>US 2002151538 A1 20021017 US 2001-915379 20010727<br>US 2002173504 A1 20021121 US 2001-915519 20010727<br>US 2002045747 A1 20020418 US 2001-916282 20010730<br>US 2002055500 A1 20020509 US 2001-916440 20010730<br>PRAI US 1996-64851P P 19961223<br>US 1997-996422 A 19971222<br>US 1998-102726 A 19980622<br>US 1996-780025 A 19961223<br>WO 1998-US22637 W 19981029<br>OS MARPAT 131:73572<br>GI |      |          |                 |          |



AB R1(NHCHR2CO)nNHW [W = Q1, Q2, etc.; R1 = H, blocking group; R2 = H, (substituted) alkyl, alkenyl, alkynyl, acyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclyl; A, B = atoms to form aryl, (substituted) cycloalkyl, cycloalkenyl, heteroaryl, heterocyclic ring;

R3 = H, (substituted) alkyl, alkenyl, alkynyl, acyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclyl; R4 = (substituted) alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclyl; m, n = 0-2], were prepd. Thus, 7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one (prepn. given) in PhMe was treated with Bu nitrite; the mixt at 0.degree. was treated with KN(SiMe3)2 followed by 1 h stirring to give 80% 7-methyl-5-oximo-5,7-dihydro-6H-dibenz[b,d]azepin-6-one. The latter was hydrogenated in EtOH over Pd/C at 35 psi to give 61% 5-amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one hydrochloride. Title compds. at 10 .mu.g/mL inhibit .beta.-amyloid prodn. by .gtoreq.30%.

IT 209984-35-0P 209984-36-1P 209984-39-4P  
209984-40-7P 209984-43-0P 209984-44-1P  
209985-07-9P 209985-08-0P 209985-09-1P  
209994-99-0P 228877-28-9P 228877-29-0P  
228877-30-3P 228877-31-4P 228877-32-5P  
228877-33-6P 228877-34-7P 228877-35-8P  
228877-36-9P 228877-37-0P 228877-38-1P  
228877-39-2P 228877-40-5P 228877-41-6P  
228877-42-7P 228877-43-8P 228877-44-9P  
228877-45-0P 228877-46-1P 228877-47-2P  
228877-48-3P 228877-49-4P 228877-50-7P  
228877-51-8P 228877-52-9P 228877-53-0P  
228877-54-1P 228877-58-5P 228877-59-6P  
228877-64-3P 228877-95-0P 229021-47-0P  
229021-48-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of annelated caprolactams as inhibitors of .beta.-amyloid release and/or synthesis)

RN 209984-35-0 CAPLUS

CN Propanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-36-1 CAPLUS  
 CN Propanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-39-4 CAPLUS  
 CN Butanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 209984-40-7 CAPLUS

CN Butanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 209984-43-0 CAPLUS

CN Butanamide, 2-amino-N-[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3,3-dimethyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 209984-44-1 CAPLUS  
 CN Butanamide, 2-amino-N-[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3,3-dimethyl-, monohydrochloride, (2S)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 209985-07-9 CAPLUS  
 CN Butanamide, 2-amino-N-(5-hexyl-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HCl

RN 209985-08-0 CAPLUS

CN Butanamide, 2-amino-N-(2-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 209985-09-1 CAPLUS

CN Butanamide, 2-amino-N-(10-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 209994-99-0 CAPLUS  
 CN Propanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 228877-28-9 CAPLUS  
 CN Carbamic acid, [(1S)-2-[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 228877-29-0 CAPLUS  
 CN Carbamic acid, [(1S)-1-[[[(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 228877-30-3 CAPLUS  
 CN Butanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 228877-31-4 CAPLUS  
 CN Carbamic acid, [(1S)-1-[[[6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 228877-32-5 CAPLUS  
 CN Butanamide, 2-amino-N-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3,3-dimethyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228877-33-6 CAPLUS  
 CN Carbamic acid, [(1S)-2-[(9-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-34-7 CAPLUS

CN Propanamide, 2-amino-N-(9-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-35-8 CAPLUS

CN Carbamic acid, [(1S)-2-[(10-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 228877-36-9 CAPLUS

CN Propanamide, 2-amino-N-(10-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-

dibenz[b,d]azepin-7-yl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-37-0 CAPLUS

CN Carbamic acid, [(1S)-2-[(2S)-2-amino-1-methyl-2-oxoethyl]-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-38-1 CAPLUS

CN Propanamide, 2-amino-N-(2-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-39-2 CAPLUS

CN Carbamic acid, [(1S)-2-[[5-(cyclopropylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-40-5 CAPLUS

CN Propanamide, 2-amino-N-[5-(cyclopropylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 228877-41-6 CAPLUS

CN Carbamic acid, [(1S)-2-[[6,7-dihydro-6-oxo-5-(4-phenylbutyl)-5H-

dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl  
ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-42-7 CAPLUS

CN Propanamide, 2-amino-N-[6,7-dihydro-6-oxo-5-(4-phenylbutyl)-5H-dibenz[b,d]azepin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 228877-43-8 CAPLUS

CN Carbamic acid, [(1S)-1-[[[5-(cyclopropylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl  
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 228877-44-9 CAPLUS

CN Butanamide, 2-amino-N-[5-(cyclopropylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-45-0 CAPLUS

CN Carbamic acid, [(1S)-1-[[[6,7-dihydro-6-oxo-5-(4-phenylbutyl)-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-46-1 CAPLUS

CN Butanamide, 2-amino-N-[6,7-dihydro-6-oxo-5-(4-phenylbutyl)-5H-dibenz[b,d]azepin-7-yl]-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-47-2 CAPLUS

CN Carbamic acid, [(1S)-1-[[[5-hexyl-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-48-3 CAPLUS

CN Butanamide, 2-amino-N-(5-hexyl-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-49-4 CAPLUS

CN Carbamic acid, [(1S)-1-[[[9-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-50-7 CAPLUS

CN Butanamide, 2-amino-N-(9-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 228877-51-8 CAPLUS

CN Carbamic acid, [(1S)-1-[[[10-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-2-methylpropyl]-, 1,1-

dimethylethyl  
ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-52-9 CAPLUS

CN Butanamide, 2-amino-N-(10-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-53-0 CAPLUS

CN Carbamic acid, [(1S)-1-[[2-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl  
ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-54-1 CAPLUS

CN Butanamide, 2-amino-N-(2-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228877-58-5 CAPLUS

CN Carbamic acid, [(1S)-1-methyl-2-oxo-2-[(5,6,8,9-tetrahydro-8-oxo-4H-benzo[d]pyrido[3,2,1-jk][1]benzazepin-9-yl)amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



The chemical structure shows a complex polycyclic aromatic system. It features a benzene ring fused to a seven-membered ring, which is further fused to a pyridine ring. A carbonyl group (C=O) is attached to the seven-membered ring. A side chain is attached to the seven-membered ring, consisting of a methylene group (CH<sub>2</sub>) and a chiral center. The chiral center is bonded to a methyl group (Me), a sulfur atom (S), and an amino group (NH<sub>2</sub>).


|    |   |        |
|----|---|--------|
| RN | 228877-64-3   | CAPLUS |
| CN | Butanamide, 2-amino-N-(9-fluoro-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-3-methyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME) |        |

CN1C(=O)C2c3ccccc3N(C)C2c4cc(F)ccc4NC(=O)C[C@H](N)S[C@@H](C)C

HCl

RN 228877-95-0 CAPLUS  
 CN Propanamide, 2-amino-N-(5,6,8,9-tetrahydro-8-oxo-4H-benzo[d]pyrido[3,2,1-jk][1]benzazepin-9-yl)-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 229021-47-0 CAPLUS  
 CN Carbamic acid, [(1S)-2-[(1,2,4,5,6,7-hexahydro-2-oxo-3,7-methano-3H-3-benzazonin-1-yl)amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 229021-48-1 CAPLUS  
 CN Propanamide, 2-amino-N-(1,2,4,5,6,7-hexahydro-2-oxo-3,7-methano-3H-3-benzazonin-1-yl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 209984-33-8P 209984-34-9P 209984-37-2P  
209984-38-3P 209984-41-8P 209984-42-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT


(Reactant or reagent)

(prepn. of annelated caprolactams as inhibitors of .beta.-amyloid  
release and/or synthesis)

RN 209984-33-8 CAPLUS

CN Carbamic acid, [(1S)-2-[[ (7S)-6,7-dihydro-5-methyl-6-oxo-5H-  
dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl  
ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-34-9 CAPLUS

CN Carbamic acid, [(1S)-2-[[ (7R)-6,7-dihydro-5-methyl-6-oxo-5H-  
dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl  
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209984-37-2 CAPLUS

CN Carbamic acid, [(1S)-1-[[[ (7S)-6,7-dihydro-5-methyl-6-oxo-5H-  
dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-  
dimethylethyl  
ester (9CI) (CA INDEX NAME)




Absolute stereochemistry.



RN 209984-38-3 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-41-8 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209984-42-9 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(7R)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]carbonyl]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT